Semaglutide in CFRD

Inclusion Criteria: Adult subjects 18 years or older with CFRD and on insulin treatment BMI >26 kg/m2 Diagnosis of pancreatic insufficiency (based on treatment with pancreatic enzyme replacement therapy) A participant who is capable of becoming pregnant must agree to take precautions that are effective in preventing pregnancy throughout this study. These methods could include one of the following 1. Complete abstinence from sexual intercourse; 2. Oral, injectable, or implanted hormonal contraceptives 3. Intrauterine device 4. Tubal ligation Exclusion Criteria: personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) acute pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to baseline study procedures gastrointestinal(GI) symptom exacerbation defined by current nausea/vomiting or diarrhea at the baseline assessment history of chronic GI problems requiring hospitalization in the 1 year prior to baseline history of clinically symptomatic pancreatitis history of clinically significant gastroparesis history of eating disorders less than 24 weeks since start of a new CFTR corrector/modulator therapy pregnancy or lactation severe CF liver disease chronic kidney disease history of suicide attempts or active suicidal ideation Non-English speakers and those unable to read in English